This fall, the iReceptor team put together some statistics about the iReceptor Gateway's user demographics, by amount, region, and affiliation. If you'd like more information on our demographics, please get in touch at: support@ireceptor.org.
The iReceptor and iReceptor Plus Projects were highlighted at the 2019 Science Gateways Conference, which took place on September 23 - 25, 2019 in San Diego, California.
External network access to our service provider, Compute Canada, will be interrupted for at least 1 hour during a 3-hour network maintenance window from 7:00 - 10:00 pm (PDT) / 10:00 pm - 1:00 am (EDT). The iReceptor Gateway and the iReceptor Public Archive repositories will be unavailable at this time.
463M annotated sequences added from two new studies: Vergani, et al. (37M) "Novel Method for High-Throughput Full-Length IGHV-D-J Sequencing of the Immune Repertoire from Bulk B-Cells with Single-Cell Resolution" and Pogorelyy, et al. (426M) "Precise tracking of vaccine-responding T cell clones reveals convergent and personalized response in identical twins" were added to the iReceptor Public Archive.
Data from two new studies totaling 154M annotated sequence have been added to the iReceptor Public Archive. Details of the two studies are given below:
27M annotated sequences added from Stern, et al. "B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes" added to the iReceptor Public Archive.
Technical problems experienced over the last week have been resolved. All iReceptor services (Gateway and Repositories) are back on line.
Compute Canada, our service provider, is experiencing file systems problems. As a result, the iReceptor Scientific Gateway is termporarily out of service. We will update the news annoucnement here when service is restored.
Compute Canada, our service provider, is experiencing file system problems. The iReceptor Public Archive is offline. Data on the iReceptor Scientific Gateway is currently limited to the data provided by VDJServer.
Data from three new studies of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma, glioblastoma, and primary liver carcinoma have been added. Details of the three studies are given below:
